...
首页> 外文期刊>Malaria Journal >Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum
【24h】

Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum

机译:氯喹治疗的苏丹恶性疟原虫患者pfcrt等位基因CVMNK和CVIET的动态

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Parasite resistance to the anti-malarial drug chloroquine is common in eastern Sudan. Dynamic within-host changes in the relative abundance of both sensitive and resistant Plasmodium falciparum parasites were examined in a cohort of chloroquine-treated patients presenting with uncomplicated falciparum malaria, using a novel allele-specific quantitative approach. Methods Treatment outcomes were determined for 93 patients of all ages in a per protocol cohort using a modified 14-day WHO protocol. Parasite DNA samples at days 0, 1, 2, 3, 7 and 14 following treatment were analysed using real-time quantitative PCR methods that distinguished resistant and sensitive genotypes at amino acids 72 - 76 of the pfcrt locus. Results Chloroquine treatment was not efficacious, and of 93 assessable patients, only 10 individuals (10.7%; 95% C.I. 4.34 - 17.2%) enjoyed an adequate clinical and parasitological response. Resistant parasites with the haplotype CVIET at codons 72-76 of the pfcrt locus were dominant in the starting population. Chloroquine sensitive parasites with the haplotype CVMNK were detected in 19 individuals prior to treatment (20.43%; 95% C.I. 5.14 - 18.5%). In these patients, CQ treatment rapidly selected CVIET parasites, and this haplotype overwhelmingly dominated the parasite population in each individual by day 2 after treatment. Conclusions Such rapid intra-host selection of particular genotypes after the introduction of drug will cause frequent misidentification of parasite genotypes present in the starting population. This will have a potentially serious confounding effect on clinical trials which employ PCR-corrected estimates of treatment failure, as resistant parasites below the detection threshold in the pre-treatment sample can be erroneously classified as "new" infections during follow-up, over-estimating drug efficacy.
机译:背景技术在苏丹东部,抗疟药氯喹对寄生虫的抵抗力很普遍。使用新颖的等位基因特异性定量方法,在一组接受氯喹治疗且无复杂恶性疟疾的患者中检查了敏感和耐药性恶性疟原虫寄生虫相对丰度的动态宿主内部变化。方法采用改良的14天WHO方案,在每个方案队列中确定93名所有年龄段患者的治疗结果。使用实时定量PCR方法分析处理后第0、1、2、3、7和14天的寄生虫DNA样品,该方法可区分pfcrt基因座第72-76位氨基酸的抗性和敏感基因型。结果氯喹治疗无效,在93名可评估的患者中,只有10个人(10.7%; 95%C.I. 4.34-17.2%)获得了充分的临床和寄生虫学反应。在pfcrt基因座的第72-76位密码子处具有单倍型CVIET的抗性寄生虫在初始种群中占主导地位。治疗前在19位个体中检出了具有单倍型CVMNK的氯喹敏感寄生虫(20.43%; 95%C.I. 5.14-18.5%)。在这些患者中,CQ治疗迅速选择了CVIET寄生虫,并且这种单倍型在治疗后第2天以绝对优势控制了每个个体的寄生虫种群。结论引入药物后对特定基因型的如此快速的宿主内选择将导致频繁错误识别起始人群中存在的寄生虫基因型。对于采用PCR校正后的治疗失败估计的临床试验,这可能会产生严重的混淆影响,因为在后续治疗,随访期间,治疗前样本中低于检测阈值的抗药性寄生虫可能被错误地归类为“新”感染。估计药物功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号